Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
UX-DA001
- Development stage
- Phase 1
- Lead developer
- UniXell Biotechnology
- Modality
- iPSCs → Pluripotent Stem Cells → Stem Cell Therapies → Cell Therapies
- Administration
- Intracerebral
01
Overview
UX-DA001 is an investigational autologous induced pluripotent stem cell (iPSC)-derived neural progenitor cell therapy developed for the treatment of Parkinson's disease. The therapy is produced by reprogramming a patient's own peripheral blood cells into iPSCs, which are then differentiated in vitro into midbrain dopaminergic progenitor cells. These cells are subsequently transplanted into the patient's brain via minimally invasive stereotactic surgery. Once integrated, the cells are intended to mature into functional dopaminergic neurons that restore dopamine production and improve motor function. By utilizing the patient's own cells, UX-DA001 aims to significantly reduce the risk of immune rejection and eliminate the need for long-term immunosuppressive therapy, potentially offering a safer and more durable treatment option compared to standard pharmacological interventions.
- Other names
- Human Midbrain Dopaminergic Progenitor Cells Injectionautologous iPSC-derived neural progenitor cell drug
Beyond the preview
Go deeper on UX-DA001.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on UX-DA001.